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ABSTRACT 
Non-steroidal analogs of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] represent a most particular class of analogs 
because they are either not directly derived from the core 1,25(OH)2D3-structure or they have modifications in 
the core structure that are so drastic that the steroidal structure is lost. Non-steroidal CD-ring analogs of 
1,25(OH)2D3 have been developped to study the role of the central rigid CD-ring system in the biological 
activity of 1,25(OH)2D3. Here we review the different classes of CD-ring analogs and highlight some 
representative analogs such as the fluorinated D-ring analogs CD578, WU515 and WY1113 which show 
markedly increased differentiating activity on human SW480-ADH colon cancer cells, characterized by a 
stronger induction of the invasion suppressor E-cadherin and a stronger repression of the β-catenin/TCF target 
oncogene c-Myc. Correspondingly, CD578, WU515 and WY1113 are more potent inhibitors of β-catenin/TCF 
signaling than 1,25(OH)2D3 and induce stronger VDR-coactivator interactions. Underlying the increased 
biological potency of analog CD578 are additional contacts between the side chain fluorine atoms of the analog 
with specific residues of helix 12 (H12) of the Vitamin D Receptor (VDR) and subsequent stronger VDR-
coactivator interactions. 
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INTRODUCTION 
1,25-Dihydroxyvitamin D3  [1,25(OH)2D3] is a key regulator of calcium/phosphate levels and bone maintenance 
and acts through the Vitamin D Receptor (VDR), a member of the nuclear receptor superfamily, which can 
heterodimerize with the Retinoid X Receptor (RXR) and binds to Vitamin D Response Elements (VDREs) in the 
promoter region of target genes [1]. Beside the actions on calcium and bone, 1,25(OH)2D3 has a potent growth-
inhibitory or antiproliferative and prodifferentiating action on different cell types including malignant cancer 
cells, mostly characterized by a G1/S arrest in the cell cycle [2]. It has become clear that, depending on the cell 
type, 1,25(OH)2D3 can use different pathways or combinations of pathways to establish its antiproliferative 
effect. Cyclins, cyclin dependent kinases (CDKs), CDK inhibitors, E2F transcription factors and their binding 
partners from the Retinoblastoma family are mostly the point of convergence between the different pathways [3]. 
In theory, its potent antiproliferative action combined with the presence of the VDR in a large array of cell types, 
would make 1,25(OH)2D3 a powerful drug to treat hyperproliferative disorders. However, the calcemic actions 
obstruct the clinical applicability of 1,25(OH)2D3. Administration of the required doses to fully benefit from the 
antiproliferative action, can result in severe hypercalcemia, hypercalciuria and bone resorption. For this reason, 
structural analogs of 1,25(OH)2D3 with an improved antiproliferative/prodifferentiating action and lower 
calcemic effects have been designed. The analogs can have modifications in the side chain of 1,25(OH)2D3, in 
the central CD-ring system, in the seco-B,A-ring system or can have combinations of modifications in two or 
even all three of these target regions [3]. Here we review a particular class of non-steroidal analogs which were 
developed in order to study the importance of the less accessible CD-ring system in the biological actions of 
1,25(OH)2D3.  
NON-STEROIDAL CD-RING ANALOGS OF 1,25(OH)2D3 
Different series of CD-ring modified analogs of 1,25(OH)2D3 have been designed among which analogs in which 
the steroidal structure was lost due to the drastic changes in this ring structure (Figure 1). The most basic non-
steroidal compound is the acyclic analog KS018 in which 1,25(OH)2D3 is completely stripped to its five carbon 
backbone. KS018 does not bind to the VDR and lacks all biological activity. Introduction of an unnatural, five-
membered ‘E-ring’ in KS018 (analog KS176) resulted in 10% VDR binding (in comparison with 1,25(OH)2D3), 
minor antiproliferative action and negligible calcemic effects [4]. Remarkably, re-introduction of the six-
membered C-ring (15-nor C-ring analogs e.g. ZG1368) or the five-membered D-ring (9,11-bisnor D-ring 
analogs e.g. SL117) generally results in an increased dissociation ratio between antiproliferative potency and 
calcemic effects in comparison with 1,25(OH)2D3 [5]. As such the D-ring analog WU515, which has an 
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additional 23-yne-26,27-F6 modification, displays an 800-fold increased antiproliferative/calcemic ratio. The 
best selectivity profile within the C- and D-ring analogs is obtained with the 19-nor-16-ene-26,27-bishomo C-
ring analog CY616 for which the antiproliferative/calcemic ratio is 1200-fold higher than for 1,25(OH)2D3 [5]. 
The CE-ring and CF-ring analogs represent two additional classes of non-steroidal analogs in which the D-ring 
has been deleted and a connection was made between C12 and C21 or between C18 and C21, respectively. The 
CE-ring analogs (eg. analogs XU248 and SD65) have very low or do not display antiproliferative actions on 
MCF-7 human breast cancer cells. The CF-ring analogs (eg. SW123) have low VDR affinity (<10%) as well as 
low calcemic actions (<1%) in comparison with 1,25(OH)2D3 [6, 7]. SW123 is five times more potent in 
inhibiting MCF-7 cell proliferation and is more than 200 times less calcemic than 1,25(OH)2D3. The introduction 
of a 22-oxa-23-yne-26,27-F6 side chain (analog FDB198E) further enhanced the antiproliferative action and 
reduced the calcemic effects of SW123 [8]. 
SUPERAGONISTIC ACTION OF D-RING ANALOGS CD578, WU515 AND WY1113 
Recently, we determined the actions of the three potent non-steroidal D-ring analogs CD578 (17-methyl-19-nor-
21-nor-23-yne-26,27-F6-1,25(OH)2D3-D-ring analog), WU515 (23-yne-26,27-F6-1,25(OH)2D3-D-ring analog) 
and WY1113 (17-methyl-19-nor-20-epi-26,27-F6-1,25(OH)2D3-D-ring analog) (Figure 1) on colon cancer cells 
[9]. These D-ring analogs with fluorinated side chains have up to 200-fold higher antiproliferative action on 
MCF-7 breast cancer cells with calcemic actions ranging from equal to those of 1,25(OH)2D3 to 100-fold lower. 
When treated with 1,25(OH)2D3, SW480-ADH colon cancer cells undergo differentiation characterized by an 
increase in adhesiveness and the formation of cell islands [10]. CD578, WU515 and WY1113 have the same 
prodifferentiating action on SW480-ADH cells, albeit at a significantly lower dose than 1,25(OH)2D3. The 
increased prodifferentiating action of the three analogs is characterized by a stronger induction of the invasion 
suppressor E-cadherin. Furthermore, treatment of SW480-ADH colon cancer cells with CD578, WU515 or 
WY1113 leads to a significantly more potent inhibition of β-catenin/TCF transcriptional activity in comparison 
with 1,25(OH)2D3 (Table 1) and a subsequent lower expression of the β-catenin/TCF target oncogene c-Myc [9]. 
CD578, WU515 and WY1113 show an at least 2-fold stronger VDR-based transactivation potency in 
comparison with 1,25(OH)2D3 and all three analogs are stronger inducers of VDR – coactivator interactions than 
1,25(OH)2D3  (Table 1). CD578, WU515 and WY1113 are fluorinated on C26 and C27 of the side chain, a 
chemical modification that is often used to make analogs of 1,25(OH)2D3 more resistant to degradation by 
CYP24; a C-F bond better withstands cleavage and radical oxidation than a C-H bond. The basic fluorinated 
analog 26,27-F6-1,25(OH)2D3 (falecalcitriol) was shown to be resistant to CYP24-mediated catabolism and had a 
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higher T1/2 than the parent compound [11]. Both antiproliferative and calcemic actions are tenfold more potent 
for falecalcitriol. The abovementioned stronger VDR – coactivator interactions for CD578, WU515 and 
WY1113 could not be explained by differences in resistance to catabolism between the three analogs and 
1,25(OH)2D3 as was demonstrated by the use of VID400, a selective inhibitor of the 1,25(OH)2D3-metabolizing 
enzyme 24-hydroxylase (CYP24) [12]. Analog CD578 was cocrystallized in complex with the zebrafish (z)VDR 
and an LXXLL-motif containing SRC-1 peptide. The zVDR Ligand Binding Domain (LBD) was previously 
shown to be similar to the structure of the human VDR LBD in complex with 1,25(OH)2D3 [13]. In comparison 
with 1,25(OH)2D3, CD578 looses contact with residue Leu258 of the zVDR due to the missing C-ring. 
Furthermore, fewer interactions with Trp314 were observed. The fluorine atoms on CD578 interact with Val444 
and Phe448 of the activation helix 12 (H12) of the zVDR and with Leu440 in the H11-H12 loop within a 
distance cutoff of 4.0Å. 1,25(OH)2D3 makes no contacts with H12 within the same distance cutoff. Stabilization 
of H12 in the zVDR-CD578 complex through the abovementioned additional contacts, causes the SRC-1 
coactivator peptide to make additional contacts with the VDR in the zVDR-CD578 complex as compared to the 
zVDR-1,25(OH)2D3 complex [9].  
CONCLUSIONS 
The non-steroidal CD-ring analogs of 1,25(OH)2D3 are an ultimate tool to study the impact of drastic changes at 
the CD-ring system, and of the combination of changes at the CD-ring with other modifications, on the 
biological activity of 1,25(OH)2D3. The D-ring analogs CD578, WU515 and WY1113, for example, show a 
significantly stronger differentiating action on human colon cancer cells caused by a stronger inhibition of β-
catenin/TCF signaling and more potent induction of VDR-coactivator interactions. In addition, the side chain 
fluorine atoms on these three analogs not only protect them from CYP24-mediated metabolic degradation but 
also contribute to increased stability of the activation H12 of the VDR.  
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FIGURE LEGENDS 
Fig.1. Non-steroidal analogs of 1,25(OH)2D3 with major modifications in the CD-ring system. 
In addition to the most basic non-steroidal, acyclic analog KS018 five different classes of non-steroidal analogs 
are shown with drastic modifications in the CD-ring system. For each class first an analog with the natural A-
ring and natural side chain is shown (except for analog SW123 which has a 19-nor A-ring structure). Further 
down are analogs with additional A-ring or side chain modifications. 
 
 
 
